Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Adjuvant effect of zymosan after pulmonary treatment in a mouse ovalbumin allergy model.

Authors
Young-SH; Wolfarth-MG; Roberts-JR; Kashon-ML; Antonini-JM
Source
Exp Cell Res 2013 Feb; 39(1):48-57
NIOSHTIC No.
20042005
Abstract
An association has been observed between indoor mold contamination and lung allergy and asthma. This relationship is not fully understood. 1-->3--Glucan is the major cell wall component of fungi and a good marker of fungi exposure. The objective was to evaluate the adjuvant effect of zymosan, a crude yeast cell wall preparation of 1-->3--glucan, during ovalbumin (OVA) sensitization in an allergy model. BALB/c mice were sensitized by pharyngeal aspiration with saline, 50 g of OVA, or OVA with 1, 10, 50, or 75 g of zymosan on days 0, 7, and 14. One week after sensitization, each sensitized animal group was challenged with an aspiration dose of 50 g of OVA once a week for 2 weeks. At 1 day after the last aspiration, bronchoalveolar lavage fluid and blood was collected, and markers of lung allergy and inflammation were assessed. An adjuvant effect of zymosan on OVA allergy during sensitization was observed as indicated by significant elevations in lung eosinophils, serum OVA-specific IgE, and lung IL-5 in the groups sensitized with zymosan and OVA. Pulmonary treatment with zymosan also amplified lung inflammation. Elevations were observed in lung neutrophils, TNF-a, and parameters of lung injury in the groups primed with both zymosan and OVA. In nearly all parameters, a non-linear dose-response relationship was observed in the groups primed with OVA and zymosan. The optimum adjuvant dose of zymosan was 10 g. This study demonstrated an adjuvant effect of zymosan when exposures occurred during the sensitization phase in an OVA-induced allergy model in BALB/c mice.
Keywords
Indoor-air-pollution; Molds; Respiratory-system-disorders; Pulmonary-system-disorders; Lung-disorders; Lung-irritants; Air-contamination; Allergies; Bronchial-asthma; Yeasts; Fungi; Bioassays; Biomarkers; Stimulants; Immune-reaction; Allergens; Laboratory-animals; Laboratory-testing; Sensitization; Alveolar-cells; Lung-cells; Neutrophils; Analytical-models; Dose-response; Author Keywords: 1-->3-beta-glucan; allergy; fungi; inflammation; zymosan
Contact
James M. Antonini, PhD, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, 1095 Willowdale Road (M/S 2015), Morgantown, WV 26505, USA
CODEN
ECREAL
Publication Date
20130201
Document Type
Journal Article
Email Address
jga6@cdc.gov
Fiscal Year
2013
NTIS Accession No.
NTIS Price
Identifying No.
B20130124
Issue of Publication
1
ISSN
0014-4827
NIOSH Division
HELD
Priority Area
Construction
Source Name
Experimental Cell Research
State
WV
TOP